Solid Biosciences Inc. Lease, Cost
Solid Biosciences Inc. (SLDB) reported Lease, Cost of $3.63 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-19
- Solid Biosciences Inc. lease, cost for the quarter ending 2019-12-31 was $694.00K.
- Solid Biosciences Inc. lease, cost for the quarter ending 2019-09-30 was $602.00K.
- Solid Biosciences Inc. lease, cost for the quarter ending 2019-06-30 was $602.00K.
- Solid Biosciences Inc. lease, cost for the quarter ending 2019-03-31 was $602.00K.
- Solid Biosciences Inc. lease, cost for fiscal 2025 was $3.63M, a 16.37% decline from fiscal 2024.
- Solid Biosciences Inc. lease, cost for fiscal 2024 was $4.34M, a 14.47% decline from fiscal 2023.
- Solid Biosciences Inc. lease, cost for fiscal 2023 was $5.07M, a 30.69% increase from fiscal 2022.
- Solid Biosciences Inc. lease, cost for fiscal 2022 was $3.88M, a 51.13% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.63M 10-K · filed 2026-03-19 | ||||
| 2024-12-31 | $4.34M 10-K · filed 2026-03-19 | $4.78M 10-K · filed 2025-03-06 | |||
| 2023-12-31 | $5.07M 10-K · filed 2025-03-06 | $5.25M 10-K · filed 2024-03-13 | |||
| 2022-12-31 | $3.88M 10-K · filed 2024-03-13 | ||||
| 2021-12-31 | $2.57M 10-K · filed 2024-03-13 | ||||
| 2020-12-31 | $2.56M 10-K · filed 2023-03-23 | ||||
| 2019-12-31 | $694.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $1.30M derived: sum of 2 quarters · filed 2022-03-14 | $1.90M derived: sum of 3 quarters · filed 2022-03-14 | $2.50M 10-K · filed 2022-03-14 | |
| 2019-09-30 | $602.00K 10-Q · filed 2019-11-12 | $1.20M derived: sum of 2 quarters · filed 2019-11-12 | $1.81M 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $602.00K 10-Q · filed 2019-08-14 | $1.12M 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | $602.00K 10-Q · filed 2019-05-13 | ||||
| 2018-12-31 | $2.52M 10-K · filed 2021-03-15 | ||||
| 2017-12-31 | $1.30M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |